INTRODUCTION {#s1}
============

Year by year, cancer incidence and mortality are increasing worldwide, seriously affecting human health and generating a huge economic burden. Cancer is thought to be the result of interactions between genes and environmental factors \[[@R1]\], such as tobacco use, alcohol intake, overweight and infection \[[@R2]\]. Single-nucleotide polymorphisms (SNPs) are the most common genetic alterations between individuals, and it is reported that SNPs in DNA repair genes have a relationship with a variety of cancers \[[@R3]\].

*BRCA1* is a tumor suppressor gene located on chromosome 17q21. It was mapped in 1990 and cloned in 1994 \[[@R4], [@R5]\]. The *BRCA1* gene was first identified as a strong candidate gene influencing susceptibility to breast and ovarian cancer \[[@R5]\]. BRCA1 is comprised of multiple functional domains and interacts with many proteins, including tumor suppressors, oncogenes, DNA damage repair proteins, cell cycle regulators, and transcriptional activators and repressors \[[@R6], [@R7]\]. BRCA1 deficiency can lead to defects in the S phase, G2/M phase, and spindle checkpoints, causing genetic instability and thus triggering DNA damage response, further increasing the risk of tumor formation \[[@R8]--[@R10]\]. It is reported that BRCA1 is expressed in many tissues, such as the lymph nodes, skin, bladder, cervix, liver, uterus, prostate, pancreas, lung, kidney, bone, brain, and is related to various types of cancer, including breast, ovarian, endometrial, pancreatic, prostate, and colon cancers \[[@R11]--[@R13]\].

Many studies have been conducted to examine the association between *BRCA1* polymorphisms and the risk of various cancers, including breast cancer, ovarian cancer (OC), cervical cancer, ESCC, gastric cancer, chronic myeloid leukemia (CML), and NHL \[[@R14]--[@R32]\]; however, the results remain inconsistent or even contradictory. For example, Dunning et al. found that rs799917 showed no significant association with breast cancer \[[@R14]\], while Nicoloso et al. suggested that rs799917 increased the risk of breast cancer \[[@R23]\]. Studies regarding rs1799966, rs1799950, and rs16941 are similarly inconsistent, so we performed a meta-analysis to more precisely determine the association between *BRCA1* polymorphisms and cancer risk.

RESULTS {#s2}
=======

Characteristics of the studies {#s2_1}
------------------------------

The flow diagram of the study selection process is shown in Figure [1](#F1){ref-type="fig"}. A total of 102 articles were obtained from a database search and from other sources. After duplicate removal and subsequent title and abstract assessment, 26 articles were left for further full-text review. Based on the inclusion and exclusion criteria, 19 articles remained \[[@R14]--[@R32]\]. One article containing data regarding various types of cancer was treated as independent studies \[[@R14]\], and there were seven articles containing studies of various *BRCA1* polymorphisms \[[@R14], [@R16], [@R17], [@R21], [@R22], [@R24], [@R27]\]. Altogether, 35 studies contained in 19 articles involving 28,094 cases and 50,657 controls were included in this meta-analysis. The main characteristics of the included studies are summarized in Table [1](#T1){ref-type="table"}. These articles were published from 1997 to 2016. Among them, ten articles were carried out in Caucasian populations, six in Asian populations, and three in other populations. The quality of the studies was evaluated based on a quality assessment scale ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The distributions of genotypes and allele frequencies in the cases and controls are shown in Table [2](#T2){ref-type="table"}.

![The flow diagram of included/excluded studies](oncotarget-09-8681-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  First author              Year   Country          Ethnicity            Cancer type                    Genotyping method            Control source
  ------------------------- ------ ---------------- -------------------- ------------------------------ ---------------------------- ----------------
  Dunning \[[@R14]\]        1997   UK               Caucasian            Breast cancer Ovarian cancer   ASOs hybridisation           PB
  Baynes \[[@R15]\]         2007   UK               Caucasian (＞ 98%)   Breast cancer                  Taqman                       PB
  Soucek \[[@R16]\]         2007   Czech Republic   Caucasian            Breast cancer                  PCR-RFLP                     HB
  Chang \[[@R17]\]          2008   USA              Caucasian            glioblastoma                   ParAllele SNP panel          PB
  Wang \[[@R18]\]           2009   China            Asian                Breast cancer                  PCR-PIRA                     PB
  Huo \[[@R19]\]            2009   China            Asian                Breast cancer                  PCR-PIRA                     PB
  Zhou \[[@R20]\]           2009   China            Asian                Cervical cancer                PCR-PIRA                     PB
  Dombernowsky \[[@R21]\]   2009   Denmark          Caucasian            Breast cancer                  Taqman                       PB
  Abbas \[[@R22]\]          2010   Germany          Caucasian            Breast cancer                  MALDI-TOF MS                 PB
  Nicoloso \[[@R23]\]       2010   USA              Caucasian            Breast cancer                  BigDye Terminator Reaction   NR
  Xu \[[@R24]\]             2012   USA              Mix                  SGC                            PCR-RFLP                     HB
  Zhang \[[@R25]\]          2013   China            Asian                ESCC                           PCR-RFLP                     PB
  Ricks-Santi \[[@R26]\]    2013   USA              Caucasian            Breast cancer                  TaqMan                       PB
  Wu \[[@R27]\]             2013   USA              Caucasian            Breast cancer                  Taqman                       FB
  Hasan \[[@R28]\]          2013   Saudi Arabia     Arab                 Breast cancer                  Taqman                       HB
  Kim \[[@R29]\]            2014   Korea            Asian                NHL                            PCR-PIRA                     PB
  Wójcicka \[[@R30]\]       2014   Poland           Caucasian            PTC                            iPLEX Gold system            PB
  Wang \[[@R31]\]           2015   China            Asian                Gastric cancer                 PCR-RFLP                     PB
  Gutierrez \[[@R32]\]      2016   Mexico           Latin American       CML                            Taqman                       Blood bank

SGC: Salivary Gland Carcinoma; ESCC: esophageal squamous cell carcinoma; NHL: Non-Hodgkin Lymphoma; PTC: Papillary Thyroid Carcinoma; CML: chronic myeloid leukemia; ASOs: allele-specific oligonucleotides; PCR-PIRA: PCR primer introduced restriction analysis assay; PCR-RFLP: PCR restriction fragment length polymorphism; MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; PB: population-based; HB: hospital-based; FB: family-based; NR: no record.

###### *BRCA1* polymorphisms genotype distribution and allele frequency in cases and controls

                            Genotype (*N*)   Allele frequency (*N*)   HWE    Score                                                                    
  ------------------------- ---------------- ------------------------ ------ ------- ------- ------ ------ ----- ------ ------ ------- ------ ------- ----
  rs799917                  Total            CC                       CT     TT      Total   CC     CT     TT    C      T      C       T              
  Dunning \[[@R14]\](BC)    801              342                      370    89      572     266    250    56    1054   548    782     362    0.805   13
  Dunning \[[@R14]\](OC)    223              102                      94     27      572     266    250    56    298    148    782     362    0.805   12
  Chang \[[@R17]\]          112              51                       51     10      112     55     38     19    153    71     148     76     0.010   9
  Wang \[[@R18]\]           1004             381                      483    140     1008    403    463    142   1245   763    1269    747    0.626   14
  Huo \[[@R19]\]            568              215                      283    70      624     255    285    84    713    423    795     453    0.757   14
  Zhou \[[@R20]\]           404              166                      196    42      404     158    183    63    528    280    499     309    0.410   13
  Dombernowsky \[[@R21]\]   1201             550                      496    155     4120    1756   1896   467   1596   806    5408    2830   0.187   13
  Abbas \[[@R22]\]          3136             1403                     1377   356     5470    2433   2396   641   4183   2089   7262    3678   0.168   13
  Nicoloso \[[@R23]\]       247              90                       118    39      185     90     75     20    298    196    255     115    0.465   7
  Xu \[[@R24]\]             156              71                       62     23      511     198    226    87    204    108    622     400    0.105   11
  Zhang \[[@R25]\]          1128             482                      530    116     1150    444    524    182   1494   762    1412    888    0.188   13
  Wu \[[@R27]\]             335              108                      164    63      408     120    211    77    380    290    451     365    0.354   12
  Hasan \[[@R28]\]          100              31                       37     32      100     30     36     34    99     101    96      104    0.005   7
  Kim \[[@R29]\]            687              364                      273    50      1700    828    715    157   1001   373    2371    1029   0.882   14
  Wang \[[@R31]\]           660              286                      313    61      800     302    365    133   885    435    969     631    0.204   13
  Gutierrez \[[@R32]\]      312              147                      129    36      469     200    210    59    423    201    610     328    0.737   12
  rs1799950                 Total            AA                       AG     GG      Total   AA     AG     GG    A      G      A       G              
  Dunning \[[@R14]\] (BC)   765              684                      81     0       631     550    74     7     1449   81     1174    88     0.016   10
  Dunning \[[@R14]\] (OC)   230              195                      35     0       631     550    74     7     425    35     1174    88     0.016   9
  Baynes \[[@R15]\]         2182             1955                     221    6       2273    2004   256    13    4131   233    4264    282    0.125   15
  Soucek \[[@R16]\]         305              261                      43     1       305     243    56     6     565    45     542     68     0.201   11
  Dombernowsky \[[@R21]\]   1200             1048                     147    5       4119    3589   513    17    2243   157    7691    547    0.771   13
  Abbas\[[@R22]\]           3139             2711                     417    11      5481    4762   679    40    5839   439    10203   759    0.004   10
  Xu\[[@R24]\]              156              132                      24     0       511     455    56     0     288    24     966     56     0.190   11
  rs1799966                 Total            AA                       AG     GG      Total   AA     AG     GG    A      G      A       G              
  Soucek\[[@R16]\]          449              270                      146    33      295     127    132    36    686    212    386     204    0.851   11
  Chang\[[@R17]\]           111              53                       49     9       112     56     39     17    155    67     151     73     0.028   9
  Dombernowsky \[[@R21]\]   1198             557                      508    133     4119    1850   1834   435   1622   774    5534    2704   0.535   13
  Abbas \[[@R22]\]          3140             1422                     1365   353     5487    2445   2391   651   4209   2071   7281    3693   0.073   13
  Xu \[[@R24]\]             156              80                       62     14      511     229    233    49    222    90     691     331    0.353   11
  Wu \[[@R27]\]             317              132                      143    42      386     162    182    42    407    227    506     266    0.388   12
  rs16941                   Total            AA                       AG     GG      Total   AA     AG     GG    A      G      A       G              
  Soucek \[[@R16]\]         305              130                      142    33      305     138    131    36    402    208    407     203    0.567   11
  Chang \[[@R17]\]          110              51                       48     11      109     55     36     18    150    70     146     72     0.008   9
  Dombernowsky \[[@R21]\]   1199             563                      491    145     4120    1854   1835   431   1617   781    5543    2697   0.463   13
  Xu \[[@R24]\]             156              81                       61     14      511     230    227    54    223    89     687     335    0.856   11
  Ricks-Santi \[[@R26]\]    267              121                      124    22      525     255    227    43    366    168    737     313    0.446   12
  Wójcicka \[[@R30]\]       1635             807                      667    161     2021    1074   792    155   2281   989    2940    1102   0.592   14

HWE: Hardy-Weinberg equilibrium.

Meta-analysis of rs799917 {#s2_2}
-------------------------

We assessed the association between the *BRCA1* rs799917 polymorphism and cancer risk by calculating the ORs and their 95% CI using the following five genetic models: the allele model (T vs. C), the homozygote model (TT vs. CC), the heterozygote model (CT vs. CC), the dominant model (TT+CT vs. CC), and the recessive model (TT vs. CT+CC). The main results of the meta-analysis for rs799917 polymorphism are shown in Table [3](#T3){ref-type="table"}. In total, there were sixteen studies with 11,074 cases and 18,205 controls for rs799917 polymorphism. In the overall analysis, no significant association was observed between rs799917 polymorphism and cancer risk in any genetic models (Table [3](#T3){ref-type="table"}).

###### Meta-analysis of the association between rs799917 polymorphism and cancer risk

  Subgroup              No.   T vs. C                TT vs. CC   CT vs. CC   TT+CT vs. CC           TT vs. CT+CC                                                                                                                                  
  --------------------- ----- ---------------------- ----------- ----------- ---------------------- -------------- ---------- ---------------------- ------- --------- ---------------------- ------- --------- ---------------------- ---------- ----------
  Overall               16    0.95 (0.89--1.01)^∗^   0.106       0.001       0.87 (0.75--1.02)^∗^   0.080          \< 0.001   0.98 (0.91--1.05)^∗^   0.533   0.078     0.96 (0.89--1.03)^∗^   0.241   0.022     0.88 (0.77--1.01)^∗^   0.078      \<0.001
  Ethnicity                                                                                                                                                                                                                                       
  Caucasian             7     1.00 (0.96--1.05)      0.901       0.111       1.03 (0.93--1.14)      0.608          0.187      1.02 (0.89--1.17)^∗^   0.801   0.023     1.03 (0.91--1.16)^∗^   0.680   0.041     1.04 (0.94--1.15)      0.419      0.196
  Asian                 6     0.89 (0.80--0.99)^∗^   0.032       0.006       0.72 (0.56--0.93)^∗^   0.011          0.003      0.98 (0.90--1.07)      0.653   0.291     0.92 (0.82--1.04)^∗^   0.194   0.064     0.72 (0.58--0.89)^∗^   0.003      0.013
  Others                3     0.87 (0.75--1.02)      0.078       0.842       0.81 (0.59--1.11)      0.189          0.887      0.83 (0.66--1.04)      0.101   0.802     0.82 (0.67--1.01)      0.067   0.802     0.89 (0.66--1.18)      0.410      0.971
  Cancer type                                                                                                                                                                                                                                     
  Breast cancer         8     1.01 (0.97--1.05)      0.716       0.171       1.03 (0.93--1.13)      0.607          0.484      1.03 (0.92--1.16)^∗^   0.571   0.023     1.04 (0.93--1.15)^∗^   0.484   0.037     1.03 (0.94--1.12)      0.592      0.607
  (Caucasian)           5     1.03 (0.94--1.13)^∗^   0.522       0.045       1.03 (0.92--1.15)      0.604          0.176      1.01 (0.86--1.18)^∗^   0.951   0.012     1.03 (0.89--1.19)^∗^   0.732   0.013     1.05 (0.95--1.16)      0.383      0.340
  (Asian)               2     1.04 (0.94--1.15)      0.436       1.000       1.02 (0.82--1.27)      0.838          0.818      1.13 (0.97--1.31)      0.108   0.680     1.11 (0.96--1.28)      0.165   0.785     0.96 (0.78--1.17)      0.672      0.678
  (Arab)                1     0.94 (0.64--1.39)      0.764       \-\-\--     0.92 (0.45--1.83)      0.793          \-\-\--    1.00 (0.50--1.96)      0.988   \-\-\--   0.95 (0.52--1.74)      0.878   \-\-\--   0.91 (0.51--1.65)      0.764      \-\-\--
  Other cancers                                                                                                                                                                                                                                   
  (Asian)                                                                                                                                                                                                                                         
  Cervical cancer       1     0.86 (0.70--1.05)      0.134       \-\-\--     0.64 (0.41--0.99)      0.046          \-\-\--    1.02 (0.76--1.37)      0.899   \-\-\--   0.92 (0.70--1.22)      0.566   \-\-\--   0.63 (0.41--0.95)      0.029      \-\-\--
  ESCC                  1     0.81 (0.72--0.92)      0.001       \-\-\--     0.59 (0.45--0.77)      \<0.001        \-\-\--    0.93 (0.78--1.11)      0.433   \-\-\--   0.84 (0.71--1.00)      0.045   \-\-\--   0.61 (0.48--0.78)      \< 0.001   \-\-\--
  Gastric cancer        1     0.76 (0.65--0.88)      \<0.001     \-\-\--     0.48 (0.34--0.68)      \<0.001        \-\-\--    0.91 (0.73--1.13)      0.379   \-\-\--   0.79 (0.64--0.98)      0.030   \-\-\--   0.51 (0.37--0.71)      \< 0.001   \-\-\--
  NHL                   1     0.86 (0.75--0.99)      0.032       \-\-\--     0.72 (0.52--1.02)      0.064          \-\-\--    0.87 (0.72--1.05)      0.138   \-\-\--   0.84 (0.71--1.01)      0.059   \-\-\--   0.77 (0.55--1.08)      0.125      \-\-\--
  (Caucasian)                                                                                                                                                                                                                                     
  Ovarian cancer        1     1.07 (0.85--1.36)      0.554       \-\-\--     1.26 (0.75--2.10)      0.381          \-\-\--    0.98 (0.71--1.36)      0.907   \-\-\--   1.03 (0.76--1.41)      0.846   \-\-\--   1.27 (0.78--2.07)      0.338      \-\-\--
  Glioblastoma          1     0.90 (0.61--1.34)      0.615       \-\-\--     0.57 (0.24--1.34)      0.194          \-\-\--    1.45 (0.82--2.55)      0.201   \-\-\--   1.15 (0.68--1.95)      0.593   \-\-\--   0.48 (0.21--1.09)      0.078      \-\-\--
  (other ethnicities)                                                                                                                                                                                                                             
  SGC                   1     0.82 (0.63--1.07)      0.150       \-\-\--     0.74 (0.43--1.26)      0.263          \-\-\--    0.77 (0.52--1.13)      0.179   \-\-\--   0.76 (0.53--1.09)      0.132   \-\-\--   0.84 (0.51--1.39)      0.502      \-\-\--
  CML                   1     0.88 (0.71--1.10)      0.260       \-\-\--     0.83 (0.52--1.32)      0.434          \-\-\--    0.84 (0.62--1.14)      0.250   \-\-\--   0.84 (0.63--1.11)      0.218   \-\-\--   0.91 (0.58--1.41)      0.663      \-\-\--
  Control source                                                                                                                                                                                                                                  
  PB                    11    0.94 (0.88--1.01)^∗^   0.089       0.002       0.85 (0.71--1.01)^∗^   0.065          \<0.001    0.97 (0.92--1.03)      0.343   0.126     0.96 (0.89--1.03)^∗^   0.236   0.064     0.84 (0.71--1.00)^∗^   0.056      \< 0.001
  HB                    2     0.86 (0.69--1.07)      0.172       0.578       0.80 (0.52--1.21)      0.289          0.637      0.82 (0.58--1.15)      0.240   0.512     0.81 (0.59--1.10)      0.172   0.520     0.87 (0.60--1.27)      0.477      0.838
  others                3     1.05 (0.80--1.38)^∗^   0.725       0.016       1.09 (0.68--1.74)^∗^   0.720          0.070      1.02 (0.71--1.47)^∗^   0.913   0.035     1.05 (0.71--1.55)^∗^   0.824   0.013     1.05 (0.82--1.36)      0.681      0.326
  Quality score                                                                                                                                                                                                                                   
  ≥12                   12    0.94 (0.88--1.00)^∗^   0.054       0.003       0.86 (0.73--1.01)^∗^   0.063          \<0.001    0.96 (0.91--1.02)      0.166   0.202     0.94 (0.88--1.01)^∗^   0.099   0.081     0.87 (0.75--1.02)^∗^   0.085      \<0.001
  \< 12                 4     1.01 (0.76--1.35)^∗^   0.930       0.028       0.96 (0.57--1.61)^∗^   0.864          0.057      1.14 (0.78--1.68)^∗^   0.496   0.066     1.09 (0.74--1.60)^∗^   0.672   0.036     0.94 (0.70--1.25)      0.662      0.129

SGC: Salivary Gland Carcinoma; ESCC: esophageal squamous cell carcinoma; NHL: Non-Hodgkin Lymphoma; PTC: Papillary Thyroid Carcinoma; CML: chronic myeloid leukemia; OR, odds ratio; 95% CI, 95% confidence interval; *P*OR, pool *P* value; *P*h, *P* value of heterogeneity test; ^\*^indicates that the OR, 95% Cl, and corresponding *P*OR were calculated based on the random-effects model; otherwise, the fixed-effects model was used.

In the subgroup analyses by ethnicity, we observe a significant association between rs799917 polymorphism and cancer risk among Asian populations in the allele, homozygote, and recessive models (T vs. C: OR, 0.89, 95% Cl, 0.80--0.99, *P* = 0.032; TT vs. CC: OR, 0.72, 95% Cl, 0.56--0.93, *P* = 0.011; TT vs. CT + CC: OR, 0.72, 95% Cl, 0.58--0.89, *P* = 0.003).

In the subgroup analyses by cancer type, we found that there was no significant association between rs799917 polymorphism and breast cancer risk either in the overall population or in the Caucasian, Asian, or other populations (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}), which is consistent with previous reports \[[@R33]\]. There were eight studies included in our meta-analysis regarding rs799917 polymorphism and the risk of non-breast cancer. Among these, four studies were carried out in Asian populations, and four studies carried out in Caucasian or other populations. The studies on Asians demonstrated that rs799917 polymorphism could decrease the risk of cervical cancer, ESCC, gastric cancer, and NHL in one or more genetic models (for cervical cancer: TT vs. CC: OR, 0.64, 95% Cl, 0.41--0.99, *P* = 0.046; TT vs. CT + CC: OR, 0.63, 95%Cl, 0.41--0.95, *P* = 0.029; for ESCC: T vs. C: OR, 0.81, 95% Cl, 0.72--0.92, *P* = 0.001; TT vs. CC: OR, 0.59, 95% Cl, 0.45--0.77, *P* \< 0.001; TT + CT vs. CC: OR, 0.84, 95% Cl, 0.71--1.00, *P* = 0.045; TT vs. CT + CC: OR, 0.61, 95% Cl, 0.48--0.78, *P* \< 0.001; for gastric cancer: T vs. C: OR, 0.76, 95% Cl , 0.65--0.88, *P* \< 0.001; TT vs. CC: OR, 0.48, 95% Cl, 0.34--0.68, *P* \< 0.001; TT + CT vs. CC: OR, 0.79, 95% Cl, 0.64--0.98, *P* = 0.030; TT vs. CT + CC: OR, 0.51, 95% Cl, 0.37--0.71, *P* \< 0.001; for NHL: T vs. C: OR, 0.86, 95% Cl, 0.75--0.99, *P* = 0.032, Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). The studies on Caucasians and other populations demonstrated that there was no significant association between rs799917 polymorphism and ovarian cancer, Glioblastoma, SGC and CML in any genetic models (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). *BRCA1* has been considered a risk-related gene for breast cancer, and the studies included in our meta-analysis reveal that the *BRCA1* rs799917 polymorphism plays an important role in the risk of non-breast cancer, especially in Asian populations. Due to the limited number of studies on each type of cancer, the conclusions drawn from these studies should be interpreted with caution. We require more studies on the association between rs799917 polymorphism and risk of these types of cancer to verify these conclusions, and the biological function of the polymorphism should be investigated as well.

![Stratification analyses by ethnicity between rs799917 polymorphism and cancer risk\
(**A**) allele model; (**B**) homozygous model; (**C**) dominant model; (**D**) recessive model. The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. The random-effects model was used.](oncotarget-09-8681-g002){#F2}

No significant association was observed between rs799917 polymorphism and cancer risk in subgroup analyses based on control source and quality score (Table [3](#T3){ref-type="table"}).

Meta-analysis of rs1799950, rs1799966, and rs16941 {#s2_3}
--------------------------------------------------

The main results of the meta-analysis for rs1799950, rs1799966, and rs16941 polymorphisms are shown in Table [4](#T4){ref-type="table"}.

###### Meta-analysis of the association between rs1799950, rs1799966, and rs16941 polymorphisms and cancer risk

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup        No.   G vs. A                GG vs. AA   AG vs. AA   GG+AG vs. AA           GG vs. AG+AA                                                                                                                                
  --------------- ----- ---------------------- ----------- ----------- ---------------------- -------------- --------- ---------------------- ------- --------- ---------------------- ------- --------- ---------------------- --------- ---------
  rs1799950                                                                                                                                                                                                                               

  Overall         7     0.93 (0.81--1.06)^∗^   0.257       0.062       0.44 (0.28--0.69)      \<0.001        0.300     1.00 (0.92--1.09)      0.941   0.140     0.96 (0.84--1.09)^∗^   0.535   0.095     0.44 (0.28--0.69)      \<0.001   0.308

                                                                       (excluded Xu)                                                                                                                     (excluded Xu)                    

  Ethnicity                                                                                                                                                                                                                               

  Caucasian       6     0.94 (0.86--1.01)      0.105       0.101       0.44 (0.28--0.69)      \<0.001        0.300     0.99 (0.91--1.08)      0.873   0.190     0.96 (0.88--1.05)      0.377   0.144     0.44 (0.28--0.69)      \<0.001   0.308

  Mix             1     1.44 (0.88--2.36)      0.152       \-\-\--     \-\-\--                \-\-\--        \-\-\--   1.48 (0.88--2.48)      0.138   \-\-\--   1.48 (0.88--2.48)      0.138   \-\-\--   \-\-\--                \-\-\--   \-\-\--

  Cancer type                                                                                                                                                                                                                             

  Breast cancer   5     0.89 (0.78--1.02)^∗^   0.088       0.072       0.46 (0.29--0.72)      0.001          0.233     0.98 (0.90--1.07)      0.675   0.231     0.95 (0.87--1.04)      0.280   0.135     0.46 (0.29--0.72)      0.001     0.244

  other\          2     1.22 (0.89--1.67)      0.216       0.411       0.19 (0.01--3. 30)     0.253          \-\-\--   1.39 (1.00--1.94)      0.052   0.767     1.32 (0.95--1.83)      0.103   0.574     0.18 (0.01--3.18)      0.242     \-\-\--
  cancers                                                                                                                                                                                                                                 

                                                                       (excluded Xu)                                                                                                                     (excluded Xu)                    

  rs1799966                                                                                                                                                                                                                               

  Overall         6     0.89 (0.78--1.02)^∗^   0.091       0.001       0.86 (0.69--1.09)^∗^   0.207          0.038     0.87 (0.73--1.03)^∗^   0.112   0.005     0.86 (0.72--1.02)^∗^   0.087   0.002     0.95 (0.86--1.06)      0.372     0.119

  Ethnicity                                                                                                                                                                                                                               

  Caucasian       5     0.90 (0.78--1.04)^∗^   0.148       0.001       0.86 (0.67--1.11)^∗^   0.252          0.020     0.89 (0.73--1.07)^∗^   0.206   0.003     0.87 (0.72--1.06)^∗^   0.161   0.001     0.92 (0.75--1.14)^∗^   0.445     0.068

  Mix             1     0.85 (0.64--1.12)      0.239       \-\-\--     0.82 (0.43--1.56)      0.542          \-\-\--   0.76 (0.52--1.11)      0.159   \-\-\--   0.77 (0.54--1.11)      0.157   \-\-\--   0.93 (0.50--1.73)      0.818     \-\-\--

  Cancer type                                                                                                                                                                                                                             

  Breast cancer   4     0.90 (0.76--1.05)^∗^   0.180       \<0.001     0.89 (0.68--1.16)^∗^   0.382          0.016     0.85 (0.70--1.04)^∗^   0.114   0.002     0.85 (0.69--1.05)^∗^   0.127   \<0.001   0.96 (0.79--1.17)^∗^   0.665     0.093

  Other\          2     0.86 (0.69--1.08)      0.200       0.825       0.72 (0.43--1.21)      0.215          0.499     0.91 (0.66--1.24)      0.533   0.109     0.86 (0.64--1.16)      0.281   0.328     0.74 (0.45--1.23)      0.251     0.240
  cancers                                                                                                                                                                                                                                 

  rs16941                                                                                                                                                                                                                                 

  Overall         6     1.05 (0.99--1.12)      0.130       0.147       1.14 (0.99--1.31)      0.064          0.271     1.03 (0.88--1.19)^∗^   0.734   0.055     1.03 (0.90--1.18)^∗^   0.642   0.082     1.14 (1.00--1.31)      0.052     0.257

  Ethnicity                                                                                                                                                                                                                               

  Caucasian       5     1.06 (1.00--1.13)      0.059       0.293       1.17 (1.01--1.35)      0.033          0.346     1.06 (0.91--1.24)^∗^   0.444   0.072     1.05 (0.97--1.14)      0.233   0.150     1.17 (1.01--1.33)      0.033     0.241

  Mix             1     0.82 (0.62--1.08)      0.158       \-\-\--     0.74 (0.39--1.40)                     \-\-\--   0.76 (0.52--1.12)      0.162   \-\-\--   0.76 (0.53--1.09)      0.130   \-\-\--   0.83 (0.45--1.55)      0.565     \-\-\--

  Cancer type                                                                                                                                                                                                                             

  Breast cancer   3     1.01 (0.93--1.10)      0.820       0.772       1.09 (0.90--1.31)      0.376          0.905     0.95 (0.84--1.06)      0.356   0.143     0.97 (0.87--1.09)      0.634   0.304     1.12 (0.94--1.34)      0.208     0.584

  Other\          3     1.00 (0.78--1.27)^∗^   0.970       0.055       0.97 (0.57--1.64)^∗^   0.909          0.064     1.09 (0.96--1.23)      0.196   0.109     1.03 (0.77--1.37)^∗^   0.864   0.087     0.95 (0.58--1.57)^∗^   0.840     0.069
  cancers                                                                                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OR, odds ratio; 95% CI, 95% confidence interval; *P*OR, pool *P* value; *P*h, *P* value of heterogeneity test; \*indicates that the OR, 95% Cl, and corresponding *P*OR were calculated based on the random-effects model; otherwise, the fixed-effects model was used.

There were seven studies with 7,997 cases and 13,951 controls examining rs1799950 polymorphism. We found that rs1799950 could decrease overall cancer risk (Table [4](#T4){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Furthermore, we found that rs1799950 could decrease cancer risk among Caucasian populations in the subgroup analyses based on ethnicity and rs1799950 could decrease breast cancer risk in the subgroup analyses based on cancer type. Because all of the studies on breast cancer were conducted using Caucasian populations, we suggest that rs1799950 can decrease breast cancer risk among Caucasian populations in the homozygote and recessive models (GG vs. AA: OR, 0.46, 95% Cl, 0.29--0.72, *P* = 0.001; GG vs. AG + AA: OR, 0.46, 95% Cl, 0.29--0.72, *P* = 0.001, Table [4](#T4){ref-type="table"} and Figure [3](#F3){ref-type="fig"}).

![Meta-analysis between rs1799950 and rs16941 polymorphisms and cancer risk\
A and B: Stratification analyses by cancer type between rs1799950 polymorphism and cancer risk (**A**) homozygous model; (**B**) recessive model); C and D: Stratification analyses by ethnicity between rs16941 polymorphism and cancer risk (**C**) homozygous model; (**D**) recessive model). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. The fixed-effects model was used.](oncotarget-09-8681-g003){#F3}

There were six studies with 5,371 cases and 10,910 controls examining rs1799966 polymorphism. We did not find any association between rs1799966 and cancer risk, either in the overall analysis or in subgroup analyses (Table [4](#T4){ref-type="table"}).

There were six studies with 3,672 cases and 7,591 controls examining rs16941 polymorphism. We did not find association between rs16941 and overall cancer risk. However, in the subgroup analyses based on ethnicity, we found that rs16941 could increase cancer risk among Caucasian populations in the homozygote and recessive models (GG vs. AA: OR, 1.17, 95% Cl, 1.07--1.35, *P* = 0.033; GG vs. AG + AA: OR, 1.17, 95% Cl, 1.01--1.33, *P* = 0.033, Table [4](#T4){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). No significant association was observed between rs16941 polymorphism and cancer risk in the subgroup analyses based on cancer type.

Sensitivity analysis {#s2_4}
--------------------

We assessed sensitivity by omitting a single study each time. The sensitivity analysis of rs799917 showed that our data were stable in the heterozygote and dominant genetic models but unstable in the allele, homozygote and recessive models (Figure [4](#F4){ref-type="fig"} and [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). In the allele and homozygote models, after omitting the study by Dunning et al. (BC) or Nicoloso et al., rs799917 was found to significantly decrease cancer risk, and in the recessive model, after omitting the study by Dunning et al. (OC), Dombernowsky et al., or Nicoloso et al., rs799917 was found to significantly decrease cancer risk.

![Sensitivity analyses between rs799917 polymorphism and cancer risk\
(**A**): allele model; (**B**): homozygous model; (**C**): heterozygous model; (**D**): dominant model; (**E**): recessive model. The random-effects model was used.](oncotarget-09-8681-g004){#F4}

No individual study showed a significant influence on the pooled ORs for rs1799950 and rs1799966 ([Supplementary Table 3](#SD3){ref-type="supplementary-material"}), indicating that our data were relatively stable for these polymorphisms

The sensitivity analysis of rs16941 showed that the results were stable in the allele, heterozygote, and dominant models but unstable in the homozygote and recessive models ([Supplementary Table 3](#SD3){ref-type="supplementary-material"}). In the homozygote model, after omitting the study by Chang et al. or Xu et al. rs16941 was shown to increase cancer risk, and in the homozygote model, after omitting the study by Soucek et al., Chang et al., Xu et al. or Ricks-Santi et al. rs16941 was shown to increase cancer risk.

Publication bias {#s2_5}
----------------

Both Begg's test and Egger's test were performed to assess the publication bias of the studies of these SNPs. Our data revealed that there was no obvious publication bias in any of the five models for rs799917, rs1799950 and rs1799966 (Table [5](#T5){ref-type="table"}). There was publication bias in the recessive model for rs16941 (Egger's test *P* = 0.015, Table [5](#T5){ref-type="table"}).

###### Publication bias analysis

  Polymorphism   Genetic model    Egger's test   Begg's test              
  -------------- ---------------- -------------- ---------------- ------- -------
  rs799917       T vs. C          -0.08          -2.042--1.886    0.934   0.964
                 TT vs. CC        -0.46          -2.574--1.659    0.650   0.822
                 CT vs. CC        0.80           -0.915--1.998    0.439   0.444
                 TT + CT vs. CC   0.39           -1.331--1.929    0.700   0.444
                 TT vs. CT+CC     -0.70          -2.805--1.429    0.497   1.000
  rs1799950      G vs. A          -0.41          -3.838--2.777    0.697   1.000
                 GG vs. AA        -1.90          -3.500--0.657    0.130   0.260
                 AG vs. AA        -0.03          -3.051--2.983    0.978   1.000
                 GG+AG vs. AA     -0.23          -3.455--2.888    0.827   0.764
                 GG vs. AG+AA     -1.87          -3.478--0.677    0.135   0.452
  rs1799966      G vs. A          -1.09          -5.522--2.416    0.338   0.260
                 GG vs. AA        -1.04          -4.217--1.911    0.355   0.452
                 AG vs. AA        -0.84          -5.071--2.705    0.446   1.000
                 GG+AG vs. AA     -0.98          -5.465--2.606    0.381   1.000
                 GG vs. AG+AA     -0.88          -3.586--1.853    0.426   0.707
  rs16941        G vs. A          -0.90          -4.186--2.131    0.417   0.452
                 GG vs. AA        -2.21          -3.645--0.413    0.092   0.260
                 AG vs. AA        0.50           -3.152--4.537    0.643   1.000
                 GG+AG vs. AA     -0.04          -3.824--3.709    0.968   1.000
                 GG vs. AG+AA     -4.12          -3.323- -0.647   0.015   0.06

The results of the sensitivity and publication bias analyses suggest that the number of studies included in our study was insufficient, especially for rs16941. Thus, the conclusions obtained by the current research should be interpreted with caution, and more studies are required to verify these conclusions in the future.

DISCUSSION {#s3}
==========

Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred worldwide in 2012 \[[@R2]\]. Cancer is the result of a combination of genetic and environmental pressures; familial cancer is primarily based on hereditary factors, and environmental factors are the main cause of sporadic cancer \[[@R1]\]. Thus, genetic and environmental factors are both important in cancer research, including the study of association between SNPs and cancer.

*BRCA1* is a tumor suppressor gene, and its most important function is DNA repair. Thus far, many studies on *BRCA1* have been concerned with the risk of breast and ovarian cancer in *BRCA1* mutation carriers. There are several mutation types that lead to the protein inactivation of BRCA1, including frameshift, missense, nonsense, and splice mutations \[[@R13]\]. The mutation types tend to correspond with various populations and ethnicities \[[@R34]\]. Moreover, many studies have reported that *BRCA1* SNP is associated with cancer risk. For example, using data from Genome-Wide Association Study (GWAS), Li et al. investigated the associations between DNA repair pathway genes and the risk of ESCC and GC, finding *BRCA1* rs8176257 to be significantly associated with the risk of ESCC in a Han Chinese population \[[@R35]\]. In addition, Mullany et al. identified 327 SNPs that may play important roles in the regulation of miRNA expression based on the GWAS data. Two of these SNPs were significantly associated with colon cancer, one being *BRCA1* 8176318 \[[@R36]\]. To investigate the relationship between *BRCA1* SNPs and cancer risk, we conducted this meta-analysis.

Four *BRCA1* gene polymorphisms were evaluated: rs799917, rs1799950, rs1799966, and rs16941. The SNPs for the meta-analysis were selected using the following criteria: the SNP was reported to be associated with cancer risk in previous studies, the SNPs were non-synonymous, and the minor allele frequencies (MAFs) of the polymorphisms were greater than 1% in most of the populations from the 1000 Genomes Project Phase 3 ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The linkage disequilibrium (LD) of the selected SNP is shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

rs799917 is a nonsynonymous SNP, and the rs799917 C \> T variant leads to an amino acid change from proline to leucine at position 871 in the BRCA1 protein. This amino acid change may impact the interaction between miR-638 and *BRCA1* mRNA, leading to increased BRCA1 expression in rs799917 T allele carriers \[[@R23], [@R25]\]. In the meta-analysis, we revealed that rs799917 polymorphism could decrease the risk of several types of non-breast cancer. Thus, this study and previous studies have shown that rs799917 is not associated with the risk of BC \[[@R33]\]. Zhang et al. reported that there were significantly lower *BRCA1* mRNA levels among subjects with the rs799917 CC genotype than among those with the CT or TT genotypes in normal and cancerous esophageal tissues \[[@R25]\], which could explain why the risk of ESCC is lower among rs799917 T carriers.

Maia et al. performed an analysis of differential allelic expression (DAE) in *BRCA1* rs799917 heterozygous individuals (CT individuals) \[[@R37]\]. They found that in fresh blood B cells, the T allele was expressed at a higher level than the C allele in some heterozygous individuals (44%) and that the C allele was expressed at a higher level than the T allele in other heterozygous individuals (26%). Furthermore, they also found that the C allele was consistently expressed at a higher level than the T allele in breast tissue in all heterozygous individuals. This suggests that in the complex cellular environment, the DAE of *BRCA1* is not only influenced by miR-638 but also by other regulatory factors and that the regulatory factors for *BRCA1* rs799917 expression are different in fresh blood B cells and breast tissue.

rs1799950 is located in the region of exon 11 that binds Rad50, which is part of the DNA damage repair complex \[[@R38]\]. rs1799950 can be found in many families who are at a high-risk for prostate cancer \[[@R39]\]. Our meta-analysis revealed that rs1799950 could decrease the breast cancer risk among Caucasian populations. rs1799966 is located in the coding region of the COOH-terminal domain of BRCA1 (BRCT). The BRCT domain is an important signaling and protein-targeting motif in the DNA damage response system \[[@R40]\]. This suggests that rs1799966 may be important in the etiology of cancer. However, our results indicated that there was no observable association between rs1799966 and cancer risk, either in the overall or subgroup analysis. The presence of the rs16941 polymorphism has been reported to be significantly associated with the positive expression of BRCA1 protein \[[@R41]\]; however, we found that rs16941 could increase cancer risk among Caucasian populations. Therefore, we require more research to verify the results regarding rs16941 in the future.

There is nearly complete linkage disequilibrium between rs799917, rs1799966, and rs16941 in the most of the populations from the 1000 Genomes Project Phase 3 ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). However, we ultimately chose to include these three SNPs instead of choosing only one because the studies on each SNP are very limited in number and the results for all the SNPs could complement one another and thus help to verify the conclusion. In our meta-analysis, we found that rs799917, rs1799966, and rs16941 were not associated with overall cancer risk. We suggest that among Asian populations rs799917 could decrease the risk of several types of cancer. However, for rs1799966 and rs16941, there are no studies about Asian populations included in the meta-analysis. We revealed that rs16941 could increase cancer risk among Caucasians but that rs799917 and rs1799966 could not. Taking into account the limited number of included studies and the fact that there was publication bias in the studies of rs16941, we require more evidence to verify the conclusions in the future.

Our meta-analysis has certain limitations. First, we only included studies in the PubMed, Embase and Web of Science databases and those written in English. This means that some studies published in other databases and written in other languages may have been ignored. Second, the meta-analysis contained only a few types of cancer. Therefore, in the future, we will require more data regarding various types of cancer to arrive at a more comprehensive conclusion. Third, the results for rs799917 and rs16941 are unstable in some genetic models, and there is publication bias in the studies on rs16941. Thus, the conclusions drawn from the current research should be interpreted with caution. Finally, because of the limited number of included studies, this meta-analysis did not consider gene-gene or gene-environment interactions.

In conclusion, our meta-analysis suggests that rs799917 polymorphism could decrease the risk of cervical cancer, ESCC, gastric cancer, and NHL among Asian populations. We also found that rs1799950 could decrease breast cancer risk among Caucasian populations and that rs16941 could increase the overall cancer risk among Caucasian populations. Considering the limited number of cancer types in and the sample size of this meta-analysis, more studies including various types of cancer are needed to investigate the association between *BRCA1* polymorphisms and cancer risk in the future.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched the PubMed, Embase, and Web of Science databases for relevant studies about *BRCA1* polymorphisms and cancer risk that were published before July 31, 2017. The following keywords and terms were used for the search: "BRCA1" or "Breast cancer associated gene 1"; "rs799917", "Pro871leu", "rs1799950", "Gln356Arg", "rs1799966", "Ser1613Gly", "rs16941" or "Glu1038Gly"; "variant", "mutation", "polymorphism" or "SNP"; "cancer", "carcinoma", "neoplasm" or "tumor" and the combinations. Besides, the reference lists of identified studies were also screened carefully for potential articles.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

All studies included in the meta-analysis had to meet the following criteria: 1) the study investigated the association between *BRCA1* polymorphisms and cancer risk; 2) the study was a case-control or cohort study; 3) the study was written in English; 4) the study contained detailed genotyping data. We excluded comments, editorials, reviews, meta-analyses, and studies lacking sufficient data.

Data extraction {#s4_3}
---------------

Data were extracted from all eligible studies by two investigators (Gui-Ping Xu and Qing Zhao) working independently. Disagreements were resolved via discussion. The following information was extracted: name of first author, year of publication, country, cancer type, ethnicity, genotyping methods, source of controls, genotype distributions of cases and controls, and Hardy-Weinberg equilibrium (HWE) for controls. One of the studies only provides the percentage of each genotype, the complete data were obtained from the author \[[@R32]\].

Quality score {#s4_4}
-------------

The quality of the studies was independently evaluated by two reviewers (Ding Wang and Hua Zhou) based on a quality assessment scale ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Any disagreement was resolved via discussion between the two reviewers. Total scores ranged from 0 (worst) to 15 (best) \[[@R42]\].

Statistical analysis {#s4_5}
--------------------

All statistical analyses were performed using the STATA software (Version 12.0; Stata Corporation, College Station, TX, USA). ORs with corresponding 95% CIs were used to assess the strength of the association between *BRCA1* polymorphisms and cancer risk. The strength of the association was estimated in the allele genetic model (T vs. C), the homozygote model (TT vs. CC), the heterozygote model (CT vs. CC), the dominant model (TT + CT vs. CC), and the recessive model (TT vs. CT + CC). The significance of the pooled OR was determined with the Z-test, and *P*-values \< 0.05 were considered statistically significant. The heterogeneity among studies was evaluated using a chi-square-based *Q* test and quantified by I^2^ \[[@R43]\]. If the result of the heterogeneity test was *P* \> 0.1, which indicated that the heterogeneity among studies was not significant, ORs were pooled using the fixed-effects model (Mantel-Haenszel model) \[[@R44]\]. Otherwise, the random-effects model (DerSimonian and Laird model) was used \[[@R45]\]. Hardy-Weinberg equilibrium (HWE) in the control group for each study was examined using a chi-squared test and a *P* value less than 0.05 was considered as significant disequilibrium. Stratified analyses were performed based on ethnicity, cancer type, control source, and quality score. Sensitivity analyses were performed to assess the stability of the results by omitting one single study each time. Begg's test and Egger's testwere performed to examine potential publication bias \[[@R46], [@R47]\]. All *P* values were two-sided, and *P* \< 0.05 was considered as statistically significant except for the *P* value of heterogeneity.
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